Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun;9(6):e404-e413.
doi: 10.1016/S2352-3018(22)00046-7.

Associations of modern initial antiretroviral drug regimens with all-cause mortality in adults with HIV in Europe and North America: a cohort study

Adam Trickey  1 , Lei Zhang  2 , M John Gill  3 , Fabrice Bonnet  4 , Greer Burkholder  5 , Antonella Castagna  6 , Matthias Cavassini  7 , Piotr Cichon  8 , Heidi Crane  9 , Pere Domingo  10 , Sophie Grabar  11 , Jodie Guest  12 , Niels Obel  13 , Mina Psichogiou  14 , Marta Rava  15 , Peter Reiss  16 , Christopher T Rentsch  17 , Melchor Riera  18 , Gundolf Schuettfort  19 , Michael J Silverberg  20 , Colette Smith  21 , Melanie Stecher  22 , Timothy R Sterling  23 , Suzanne M Ingle  2 , Caroline A Sabin  24 , Jonathan A C Sterne  2
Affiliations

Associations of modern initial antiretroviral drug regimens with all-cause mortality in adults with HIV in Europe and North America: a cohort study

Adam Trickey et al. Lancet HIV. 2022 Jun.

Abstract

Background: Over the past decade, antiretroviral therapy (ART) regimens that include integrase strand inhibitors (INSTIs) have become the most commonly used for people with HIV starting ART. Although trials and observational studies have compared virological failure on INSTI-based with other regimens, few data are available on mortality in people with HIV treated with INSTIs in routine care. Therefore, we compared all-cause mortality between different INSTI-based and non-INSTI-based regimens in adults with HIV starting ART from 2013 to 2018.

Methods: This cohort study used data on people with HIV in Europe and North America from the Antiretroviral Therapy Cohort Collaboration (ART-CC) and UK Collaborative HIV Cohort (UK CHIC). We studied the most common third antiretroviral drugs (additional to nucleoside reverse transcriptase inhibitor) used from 2013 to 2018: rilpivirine, darunavir, raltegravir, elvitegravir, dolutegravir, efavirenz, and others. Adjusted hazard ratios (aHRs; adjusted for clinical and demographic characteristics, comorbid conditions, and other drugs in the regimen) for mortality were estimated using Cox models stratified by ART start year and cohort, with multiple imputation of missing data.

Findings: 62 500 ART-naive people with HIV starting ART (12 422 [19·9%] women; median age 38 [IQR 30-48]) were included in the study. 1243 (2·0%) died during 188 952 person-years of follow-up (median 3·0 years [IQR 1·6-4·4]). There was little evidence that mortality rates differed between regimens with dolutegravir, elvitegravir, rilpivirine, darunavir, or efavirenz as the third drug. However, mortality was higher for raltegravir compared with dolutegravir (aHR 1·49, 95% CI 1·15-1·94), elvitegravir (1·86, 1·43-2·42), rilpivirine (1·99, 1·49-2·66), darunavir (1·62, 1·33-1·98), and efavirenz (2·12, 1·60-2·81) regimens. Results were similar for analyses making different assumptions about missing data and consistent across the time periods 2013-15 and 2016-18. Rates of virological suppression were higher for dolutegravir than other third drugs.

Interpretation: This large study of patients starting ART since the introduction of INSTIs found little evidence that mortality rates differed between most first-line ART regimens; however, raltegravir-based regimens were associated with higher mortality. Although unmeasured confounding cannot be excluded as an explanation for our findings, virological benefits of first-line INSTIs-based ART might not translate to differences in mortality.

Funding: US National Institute on Alcohol Abuse and Alcoholism and UK Medical Research Council.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests MC reports grants and payments for expert testimony from Gilead, Merck, and ViiV Healthcare, paid to their institution; and payment support for attending meetings from Gilead. PC reports advisory board and expert fees from ViiV Healthcare, Gilead, and Merck; lecture fees from ViiV Healthcare and Gilead; and travel grants paid to their institution from ViiV Healthcare and Gilead. CS reports fees from Gilead for an educational presentation. MJG reports honoraria in the last 3 years from ad hoc membership of national HIV advisory boards, and from Merck, Gilead, and ViiV Healthcare. MP reports honoraria for presentations from Gilead and Merck; consulting fees from Gilead, Merck, and AbbVie; and a research grant from Gilead. FB reports travel grants and honoraria from ViiV Healthcare, Gilead, Janssen, and Merck; consulting fees and payment for expert testimony from Gilead; and support for attending meetings from Gilead, Janssen, Merck, and ViiV Healthcare. PR reports independent scientific grant support from Gilead Sciences, Merck, and ViiV Healthcare, paid to their institution; and has served on scientific advisory boards for Gilead Sciences, ViiV Healthcare, and Merck, for which honoraria were all paid to their institution, none related to the content of this Article. MRi reports funds from Gilead for attending meetings; and payment for lectures from ViiV Healthcare. MRa reports grants from Gilead. GB reports consulting fee from MedIQ; payments and honoraria from the University of Kentucky, Lexington, Kentucky, and StateServ; and funding from Merck, Eli Lily, Kaiser Permanente, and Amgen paid to their institution. HC reports research grant funding from ViiV Healthcare, National Institute of Health, and Agency for Healthcare Research and Quality, paid to their institution; and sits on the National Institute of Health Office of AIDS Research Advisory Council. NO reports funding from the Preben og Anne Simonsens Fond. CAS reports honoraria from Gilead Sciences, ViiV Healthcare, and Janssen–Cilag for membership of Data Safety and Monitoring Boards, Advisory Boards, and for preparation of educational materials; and is the vice-chair of the British HIV Association. PD reports consulting fees from Gilead, Merck, Janssen and Cilag, ViiV Healthcare, Roche, and Theratechnologies; and payment or honoraria for lectures from Gilead, Merck, Janssen, ViiV Healthcare, and Roche. All other authors declare no competing interests.

Figures

Figure
Figure
Kaplan-Meier estimates of the cumulative incidence of regimen switching *People were censored at death, loss to follow-up, or administrative censoring, whichever occurred first.
See this image and copyright information in PMC

Comment in

References

    1. The Antiretroviral Therapy Cohort Collaboration Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. Lancet HIV. 2017;4:e349–e356. - PMC - PubMed
    1. Samji H, Cescon A, Hogg RS, et al. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS One. 2013;8 - PMC - PubMed
    1. Brooks KM, Sherman EM, Egelund EF, et al. Integrase inhibitors: after 10 years of experience, is the best yet to come? Pharmacotherapy. 2019;39:576–598. - PubMed
    1. Ryom L, Cotter A, De Miguel R, et al. 2019 update of the European AIDS Clinical Society guidelines for treatment of people living with HIV version 10.0. HIV Med. 2020;21:617–624. - PMC - PubMed
    1. Saag MS, Gandhi RT, Hoy JF, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the International Antiviral Society-USA Panel. JAMA. 2020;324:1651–1669. - PMC - PubMed

Publication types